SCHEMBL5527835

SCHEMBL5527835

O/N=C(\Nc1cccc(Cl)c1)N1CCC(Cc2ccccc2)CC1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.56
KDM4E B2RXH2 2/20 0.56
MAPT P10636 2/20 0.56
GLA P06280 1/20 0.56
GAA P10253 1/20 0.56
HTT P42858 1/20 0.56
ATM Q13315 1/20 0.56
L3MBTL1 Q9Y468 1/20 0.56
FAAH O00519 3/20 0.54
KMT2A Q03164 2/20 0.53
LMNA P02545 2/20 0.52
MEN1 O00255 1/20 0.52
CCR3 P51677 4/20 0.47
NPC1 O15118 1/20 0.47
TSHR P16473 1/20 0.47
RAB9A P51151 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
TNKS O95271 1/20 0.47
PARP1 P09874 1/20 0.47
PARP14 Q460N5 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5527838 1.00 ALDH1A1 (0.56) ALDH1A1KDM4EMAPTGLAGAA
SCHEMBL17742829 0.84 FAAH (0.77) ALDH1A1KDM4EMAPTFAAHKMT2A
SCHEMBL14448415 0.84 ALDH1A1 (0.58) ALDH1A1KDM4EMAPTGLAGAA
SCHEMBL5531048 0.79 ALDH1A1 (0.64) ALDH1A1MAPTHTTL3MBTL1KMT2A
SCHEMBL5531050 0.79 ALDH1A1 (0.64) ALDH1A1MAPTHTTL3MBTL1KMT2A
SCHEMBL5527844 0.77 ALDH1A1 (0.56) ALDH1A1KDM4EMAPTGLAGAA
SCHEMBL1574908 0.76 CCR3 (0.62) ALDH1A1KDM4EMAPTFAAHKMT2A
SCHEMBL5527787 0.75 ALDH1A1 (0.57) ALDH1A1KDM4EMAPTGAAHTT
SCHEMBL5527789 0.75 ALDH1A1 (0.57) ALDH1A1KDM4EMAPTGAAHTT
SCHEMBL19873074 0.74 MEN1 (0.61) ALDH1A1KDM4EMAPTGLAGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070203140-A1 N-hydroxyguanidines as modulators of indoleamine 2,3-dioxygenase INCYTE CORPORATION 2007-08-30 US claimed
WO-2007095050-A2 N-HYDROXYGUANIDINES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE INCYTE CORPORATION (US) 2007-08-23 WO claimed
US-20070203140-A1 N-hydroxyguanidines as modulators of indoleamine 2,3-dioxygenase INCYTE CORPORATION 2007-08-30 US disclosed
US-20070203140-A1 N-hydroxyguanidines as modulators of indoleamine 2,3-dioxygenase INCYTE CORPORATION 2007-08-30 US disclosed
WO-2007095050-A2 N-HYDROXYGUANIDINES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE INCYTE CORPORATION (US) 2007-08-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070203140-A1 N-hydroxyguanidines as modulators of indoleamine 2,3-dioxygenase IDO1, IDO2, HNMT ALDH1A1 764/4885KDM4E 810/4885MAPT 2160/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.